Radiomolecular Theranostics With Fibroblast-Activation-Protein Inhibitors and Peptides

Baum, Richard P.; Novruzov, Emil; Zhao, Tianzhi; Greifenstein, Lukas; Jakobsson, Vivianne; Perrone, Elisabetta; Mishra, Aditi; Eismant, Aleksandr; Ghai, Kriti; Klein, Ortwin; Jaeschke, Bastian; Benz-Zils, Daniel; Cardinale, Jens; Mori, Yuriko; Giesel, Frederik L.; Zhang, Jingjing

doi:10.1053/j.semnuclmed.2024.05.010

Seminars in Nuclear Medicine

2024

DOI: 10.1053/j.semnuclmed.2024.05.010

|View full text |Cite

Radiomolecular Theranostics With Fibroblast-Activation-Protein Inhibitors and Peptides

Richard P. Baum,

Emil Novruzov,

Tianzhi Zhao

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 8 publications

References 89 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Design and Application of Nuclear and Molecular Theragnostic Probes

Sharma,

Chaturvedi,

Kaul

et al. 2024

ChemistrySelect

View full text Add to dashboard Cite

With growing propensity towards personalised medication, the application and impact of molecular theragnostic (or, theranostic) is expected to increase dramatically. Molecular theragnostic is the combination of diagnostics and therapeutics in single targeted molecule. If successful, molecular theragnostic will determine the treatment strategy and therapeutic outcome apart from favourably influencing the time of treatment and comfort of the patient. Recent developments such as [64Cu]Cu‐ATSM for imaging tumor‐hypoxia, 99Y silicate for arthritis, 1⁷⁷Lu‐PSMA‐617 for prostate cancer etc has been discussed in detail in the literature.[1,2] This sectioned review deals in particular with the development of nuclear molecular theragnostic agents. The genesis and design strategies are presented after compiling recent reports.

show abstract

Design and Application of Nuclear and Molecular Theragnostic Probes

Sharma,

Chaturvedi,

Kaul

et al. 2024

ChemistrySelect

View full text Add to dashboard Cite

show abstract

Development of [⁶⁸Ga]Ga/[¹⁷⁷Lu]Lu-DOTA-NI-FAPI-04 Containing a Nitroimidazole Moiety as New FAPI Radiotracers with Improved Tumor Uptake and Retention

Luo,

Jin,

Zang

et al. 2024

J. Med. Chem.

View full text Add to dashboard Cite

Clinical applications of fibroblast activation protein inhibitor positron emission tomography (FAPI-PET)

Mori,

Novruzov,

Schmitt

et al. 2024

npj Imaging

View full text Add to dashboard Cite

The discovery of fibroblast activation protein inhibitor positron emission tomography (FAPI-PET) has paved the way for a new class of PET tracers that target the tumor microenvironment (TME) rather than the tumor itself. Although 18F-fluorodeoxyglucose (FDG) is the most common PET tracer used in clinical imaging of cancer, multiple studies have now shown that the family of FAP ligands commonly outperform FDG in detecting cancers, especially those known to have lower uptake on FDG-PET. Moreover, FAPI-PET will have applications in benign fibrotic or inflammatory conditions. Thus, even while new FAPI-PET tracers are in development and applications are yet to enter clinical guidelines, a significant body of literature has emerged on FAPI-PET, suggesting it will have important clinical roles. This article summarizes the current state of clinical FAPI-PET imaging as well as potential uses as a theranostic agent.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Radiomolecular Theranostics With Fibroblast-Activation-Protein Inhibitors and Peptides

Cited by 8 publications

References 89 publications

Design and Application of Nuclear and Molecular Theragnostic Probes

Design and Application of Nuclear and Molecular Theragnostic Probes

Development of [⁶⁸Ga]Ga/[¹⁷⁷Lu]Lu-DOTA-NI-FAPI-04 Containing a Nitroimidazole Moiety as New FAPI Radiotracers with Improved Tumor Uptake and Retention

Clinical applications of fibroblast activation protein inhibitor positron emission tomography (FAPI-PET)

Contact Info

Product

Resources

About

Radiomolecular Theranostics With Fibroblast-Activation-Protein Inhibitors and Peptides

Cited by 8 publications

References 89 publications

Design and Application of Nuclear and Molecular Theragnostic Probes

Design and Application of Nuclear and Molecular Theragnostic Probes

Development of [68Ga]Ga/[177Lu]Lu-DOTA-NI-FAPI-04 Containing a Nitroimidazole Moiety as New FAPI Radiotracers with Improved Tumor Uptake and Retention

Clinical applications of fibroblast activation protein inhibitor positron emission tomography (FAPI-PET)

Contact Info

Product

Resources

About

Development of [⁶⁸Ga]Ga/[¹⁷⁷Lu]Lu-DOTA-NI-FAPI-04 Containing a Nitroimidazole Moiety as New FAPI Radiotracers with Improved Tumor Uptake and Retention